The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Dendritic Cells and Their Role in Immunotherapy
Open accessAbstract
Despite significant advances in the field of cancer immunotherapy, the majority of patients still do not benefit from treatment and must rely on traditional therapies. Dendritic cells have long been a focus of cancer immunotherapy due to their role in inducing protective adaptive immunity, but cancer vaccines have shown limited efficacy in the past. With the advent of immune checkpoint blockade and the ability to identify patient-specific neoantigens, new vaccines, and combinatorial therapies are being evaluated in the clinic. Dendritic cells are also emerging as critical regulators of the immune response within tumors. Understanding how to augment the function of these intratumoral dendritic cells could offer new approaches to enhance immunotherapy, in addition to improving the cytotoxic and targeted therapies that are partially dependent upon a robust immune response for their efficacy. Here we will discuss the role of specific dendritic cell subsets in regulating the anti-tumor immune response, as well as the current status of dendritic cell-based immunotherapies, in order to provide an overview for future lines of research and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“Similarly, the inability of tumors to recruit the cDC1 subset prevents an effective CD8 T cell response from developing (35, 36), while increasing the number of cDCs in the tumor can restore response to immunotherapy (10, 35).”
BackgroundDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 1×
“Although expensive and technically challenging, neoantigen vaccines are safe and able to induce strong systemic T cell responses (150, 151).”
BackgroundSingle-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. (2017) · Science · doi:10.1126/science.aah4573 · Cited by 2,413
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“Host STING is required for the induction of anti-tumor immunity, as STING-deficient mice fail to develop spontaneous immunity against immunogenic tumor lines and show reduced responses to radiation therapy (89, 90).”
BackgroundBatf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, E., Tussiwand, R., & Yona, S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3712 · Cited by 1,819
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H. D., Krishnan, I., Maroni, G., Meyerovitz, C. V., Kerwin, C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.009 · Cited by 1,475
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“Instead, macrophages are usually found to blunt T cell responses against tumors via multiple mechanisms and act to suppress therapeutic response to ICB as well as chemotherapy and irradiation (5, 6).”
BackgroundSelf-citationRequirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory
Shedlock, D. J., & Shen, H. (2003) · Science · doi:10.1126/science.1082305 · Cited by 1,460
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · cited 2×
“Furthermore, genes specific for cDC1 correlate with the presence of CXCL9 expression by human tumors in the TCGA database (11, 13), and cDC1 in human breast tumors exhibit expression of CXCL9 by immunofluorescence (11), further indicating that human cDC1 are likely to produce similar chemokines and play a similar role…”
BackgroundHuman dendritic cell subsets: an update
Collin, M., & Bigley, V. (2018) · Immunology · doi:10.1111/imm.12888 · Cited by 1,301
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Induction of tolerance by IL-10-treated dendritic cells
Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,246
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8056-8063.1994 · Cited by 1,157
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C.-J. J., Dunbar, P. R., Wadley, R. B., Jeet, V., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092140 · Cited by 1,027
Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Self-citationGarris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966 · cited 1×
“In support of this, cDC1 production of IL-12 was found to induce IFNγ production by CD8 T cells following PD-L1 blockade, and the feedback loop between IL-12-producing cDC1s and IFNγproducing CD8 T cells was necessary for therapeutic efficacy (12).”
BackgroundA conserved dendritic-cell regulatory program limits antitumour immunity
Maier, B., Leader, A. M., Chen, S. T., Tung, N., Chang, C., LeBerichel, J., Chudnovskiy, A., Maskey, S., Walker, L., Finnigan, J. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2134-y · Cited by 941
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933 · cited 2×
“DC-specific siRNA silencing of XBP1 led to decreased lipid accumulation by DCs and enhanced immune-mediated tumor control in mouse models of ovarian cancer (117).”
BackgroundTargeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Dendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Design of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912
Dendritic Cells and Cancer Immunity
Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 907
Self-citationRegulation of Dendritic Cell Migration to the Draining Lymph Node
Martín-Fontecha, A., Sebastiani, S., Höpken, U. E., Uguccioni, M., Lipp, M., Lanzavecchia, A., & Sallusto, F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030448 · Cited by 878
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838
Dendritic cell subsets in T cell programming: location dictates function
Eisenbarth, S. C. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0088-1 · Cited by 827
Bachem, A., Güttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A., Movassaghi, K., Opitz, C., Mages, H. W., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100348 · Cited by 822
Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species
Guilliams, M., Dutertre, C.-A., Scott, C. L., McGovern, N., Sichien, D., Chakarov, S., Van Gassen, S., Chen, J., Poidinger, M., De Prijck, S., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.015 · Cited by 822
Allan, R. S., Waithman, J., Bedoui, S., Jones, C. M., Villadangos, J. A., Zhan, Y., Lew, A. M., Shortman, K., Heath, W. R., & Carbone, F. R. (2006) · Immunity · doi:10.1016/j.immuni.2006.04.017 · Cited by 757
Duraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Lipid accumulation and dendritic cell dysfunction in cancer
Herber, D. L., Cao, W., Nefedova, Y., Novitskiy, S. V., Nagaraj, S., Tyurin, V. A., Corzo, A., Cho, H.-I., Celis, E., Lennox, B., et al. (2010) · Nature Medicine · doi:10.1038/nm.2172 · Cited by 735
Haniffa, M., Shin, A., Bigley, V., McGovern, N., Teo, P., See, P., Wasan, P. S., Wang, X.-N., Malinarich, F., Malleret, B., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.012 · Cited by 724
Itano, A. A., McSorley, S. J., Reinhardt, R. L., Ehst, B. D., Ingulli, E., Rudensky, A. Y., & Jenkins, M. K. (2003) · Immunity · doi:10.1016/s1074-7613(03)00175-4 · Cited by 718
Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716 · cited 2×
“As CXCL9 expression also correlates with response to anti-PD-1 (14), there is likely a critical role for cDC1s in the context of patient response to ICB as well, although this has not been directly tested.”
BackgroundEdelson, B. T., KC, W., Juang, R., Kohyama, M., Benoit, L. A., Klekotka, P. A., Moon, C., Albring, J. C., Ise, W., Michael, D. G., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091627 · Cited by 715
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
The function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
Vremec, D., Zorbas, M., Scollay, R., Saunders, D. J., Ardavin, C. F., Wu, L., & Shortman, K. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.1.47 · Cited by 625
Marcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 611
Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity
Brown, C. C., Gudjonson, H., Pritykin, Y., Deep, D., Lavallée, V.-P., Mendoza, A., Fromme, R., Mazutis, L., Ariyan, C., Leslie, C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.09.035 · Cited by 601
Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 574
Mapping the human DC lineage through the integration of high-dimensional techniques
See, P., Dutertre, C.-A., Chen, J., Günther, P., McGovern, N., Irac, S. E., Gunawan, M., Beyer, M., Händler, K., Duan, K., et al. (2017) · Science · doi:10.1126/science.aag3009 · Cited by 574
Antigen-Presentation Properties of Plasmacytoid Dendritic Cells
Villadangos, J. A., & Young, L. (2008) · Immunity · doi:10.1016/j.immuni.2008.09.002 · Cited by 544
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Liau, L. M., Ashkan, K., Tran, D. D., Campian, J. L., Trusheim, J. E., Cobbs, C. S., Heth, J. A., Salacz, M., Taylor, S., D’Andre, S. D., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1507-6 · Cited by 537
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Mitchell, D. A., Batich, K. A., Gunn, M. D., Huang, M.-N., Sanchez-Perez, L., Nair, S. K., Congdon, K. L., Reap, E. A., Archer, G. E., Desjardins, A., et al. (2015) · Nature · doi:10.1038/nature14320 · Cited by 531
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
Sancho, D., Mourão-Sá, D., Joffre, O. P., Schulz, O., Rogers, N. C., Pennington, D. J., Carlyle, J. R., & Reis e Sousa, C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34584 · Cited by 519
Steinbrink, K., Jonuleit, H., Müller, G., Schuler, G., Knop, J., & Enk, A. H. (1999) · Blood · doi:10.1182/blood.v93.5.1634 · Cited by 511
Engineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & De Palma, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 505
Sánchez-Paulete, A. R., Cueto, F. J., Martínez-López, M., Labiano, S., Morales-Kastresana, A., Rodríguez-Ruiz, M. E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M. A., Quetglas, J. I., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0510 · Cited by 484
Pearce, E. J., & Everts, B. (2015) · Nature Reviews Immunology · doi:10.1038/nri3771 · Cited by 483
(2003) · PubMed · Cited by 477
Sung, S.-S. J., Fu, S. M., Rose, C. E., Gaskin, F., Ju, S.-T., & Beaty, S. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2161 · Cited by 476
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer
Hegde, S., Krisnawan, V. E., Herzog, B. H., Zuo, C., Breden, M. A., Knolhoff, B. L., Hogg, G. D., Tang, J. P., Baer, J. M., Mpoy, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.008 · Cited by 463
Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer
Treilleux, I., Blay, J.-Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J.-P., Bremond, A., Goddard, S., Pin, J.-J., Barthelemy-Dubois, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0684 · Cited by 460
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Prins, R. M., Soto, H., Konkankit, V., Odesa, S. K., Eskin, A., Yong, W. H., Nelson, S. F., & Liau, L. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2563 · Cited by 451
Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms
De, S., Wirthensohn, D. C., Flagmeier, P., Hughes, C., Aprile, F. A., Ruggeri, F. S., Whiten, D. R., Emin, D., Xia, Z., Varela, J. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09477-3 · Cited by 448
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“For example, cDC2s were found to be important during response to anthracycline chemotherapy (55), and certain tumor models are responsive to adoptively transferred CD4 T cells (56).”
BackgroundDendritic cells in cancer: the role revisited
Veglia, F., & Gabrilovich, D. I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.002 · Cited by 443
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
Hammerich, L., Marron, T. U., Upadhyay, R., Svensson-Arvelund, J., Dhainaut, M., Hussein, S., Zhan, Y., Ostrowski, D., Yellin, M., Marsh, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0410-x · Cited by 436
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Self-citationMigration of human dendritic cells after injection in patients with metastatic malignancies.
Morse, M. A., Coleman, R., Akabani, G., Niehaus, N., Coleman, D., & Lyerly, H. K. (1999) · PubMed · Cited by 381
Matteoli, G., Mazzini, E., Iliev, I. D., Mileti, E., Fallarino, F., Puccetti, P., Chieppa, M., & Rescigno, M. (2010) · Gut · doi:10.1136/gut.2009.185108 · Cited by 378
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 377
Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
Eradication of spontaneous malignancy by local immunotherapy
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 361
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Theisen, D. J., Davidson, J. T., Briseño, C. G., Gargaro, M., Lauron, E. J., Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J. R., et al. (2018) · Science · doi:10.1126/science.aat5030 · Cited by 346
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Critical roles of interferon regulatory factor 4 in CD11bhighCD8α–dendritic cell development
Suzuki, S., Honma, K., Matsuyama, T., Suzuki, K., Toriyama, K., Akitoyo, I., Yamamoto, K., Suematsu, T., Nakamura, M., Yui, K., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402139101 · Cited by 318
Xu, M. M., Pu, Y., Han, D., Shi, Y., Cao, X., Liang, H., Chen, X., Li, X.-D., Deng, L., Chen, Z. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.016 · Cited by 315
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Veglia, F., Tyurin, V. A., Mohammadyani, D., Blasi, M., Duperret, E. K., Donthireddy, L., Hashimoto, A., Kapralov, A., Amoscato, A., Angelini, R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02186-9 · Cited by 308
Alcántara-Hernández, M., Leylek, R., Wagar, L. E., Engleman, E. G., Keler, T., Marinkovich, M. P., Davis, M. M., Nolan, G. P., & Idoyaga, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.001 · Cited by 301
Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells
Rodrigues, P. F., Alberti-Servera, L., Eremin, A., Grajales-Reyes, G. E., Ivanek, R., & Tussiwand, R. (2018) · Nature Immunology · doi:10.1038/s41590-018-0136-9 · Cited by 301
Dendritic Cells Display Subset and Tissue-Specific Maturation Dynamics over Human Life
Granot, T., Senda, T., Carpenter, D. J., Matsuoka, N., Weiner, J., Gordon, C. L., Miron, M., Kumar, B. V., Griesemer, A., Ho, S.-H., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.019 · Cited by 290
Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111171 · Cited by 271
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation
Vander Lugt, B., Khan, A. A., Hackney, J. A., Agrawal, S., Lesch, J., Zhou, M., Lee, W. P., Park, S., Xu, M., DeVoss, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2795 · Cited by 254
Domínguez, P. M., & Ardavín, C. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00876.x · Cited by 254
Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
Natsuaki, Y., Egawa, G., Nakamizo, S., Ono, S., Hanakawa, S., Okada, T., Kusuba, N., Otsuka, A., Kitoh, A., Honda, T., et al. (2014) · Nature Immunology · doi:10.1038/ni.2992 · Cited by 236
Adams, S., Kozhaya, L., Martiniuk, F., Meng, T.-C., Chiriboga, L., Liebes, L., Hochman, T., Shuman, N., Axelrod, D., Speyer, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1149 · Cited by 222
Alfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Marigo, I., Zilio, S., Desantis, G., Mlecnik, B., Agnellini, A. H. R., Ugel, S., Sasso, M. S., Qualls, J. E., Kratochvill, F., Zanovello, P., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.004 · Cited by 203
Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Le Mercier, I., Poujol, D., Sanlaville, A., Sisirak, V., Gobert, M., Durand, I., Dubois, B., Treilleux, I., Marvel, J., Vlach, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3058 · Cited by 195
Monocyte‐derived dendritic cells in innate and adaptive immunity
León, B., & Ardavín, C. (2008) · Immunology and Cell Biology · doi:10.1038/icb.2008.14 · Cited by 190
Robinson, R. A., DeVita, V. T., Levy, H. B., Baron, S., Hubbard, S. P., & Levine, A. S. (1976) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.599 · Cited by 189
Dendritic Cell Metabolism and Function in Tumors
Giovanelli, P., Sandoval, T. A., & Cubillos-Ruiz, J. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.004 · Cited by 187
VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1625 · Cited by 176
Dudek, A. Z., Yunis, C., Harrison, L. I., Kumar, S., Hawkinson, R., Cooley, S., Vasilakos, J. P., Gorski, K. S., & Miller, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1443 · Cited by 173
Rosenblatt, J., Stone, R. M., Uhl, L., Neuberg, D., Joyce, R., Levine, J. D., Arnason, J., McMasters, M., Luptakova, K., Jain, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1298 · Cited by 164
Zhu, Q., Man, S. M., Gurung, P., Liu, Z., Vogel, P., Lamkanfi, M., & Kanneganti, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402051 · Cited by 163
Yewdall, A. W., Drutman, S. B., Jinwala, F., Bahjat, K. S., & Bhardwaj, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011144 · Cited by 162
Kleindienst, P., & Brocker, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.2817 · Cited by 161
Granulocytes: New Members of the Antigen-Presenting Cell Family
Lin, A., & Loré, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01781 · Cited by 161
Birkholz, K., Schwenkert, M., Kellner, C., Groß, S., Fey, G. H., Schuler‐Thurner, B., Schuler, G., Schaft, N., & Dörrie, J. (2010) · Blood · doi:10.1182/blood-2010-02-268425 · Cited by 159
Antigen Presentation by MHC-Dressed Cells
NAKAYAMA, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00672 · Cited by 157
Joffre, O. P., Sancho, D., Zelenay, S., Keller, A. M., & Sousa, C. R. E. (2010) · European Journal of Immunology · doi:10.1002/eji.201040419 · Cited by 154
Wculek, S. K., Amores, J., Conde‐Garrosa, R., Khouili, S. C., Melero, I., & Sancho, D. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0565-5 · Cited by 153
Differential Intrasplenic Migration of Dendritic Cell Subsets Tailors Adaptive Immunity
Calabrό, S., Liu, D., Gallman, A. E., Nascimento, M. S. L., Yu, Z., Zhang, T., Chen, P., Zhang, B., Xu, L., Gowthaman, U., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.076 · Cited by 150
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Zanetti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402669 · Cited by 146
Diverse roles of STING-dependent signaling on the development of cancer
Ahn, J., Konno, H., & Barber, G. N. (2015) · Oncogene · doi:10.1038/onc.2014.457 · Cited by 142
Mittal, D., Vijayan, D., Putz, E. M., Aguilera, A. R., Markey, K. A., Straube, J., Kazakoff, S. H., Nutt, S. L., Takeda, K., Hill, G. R., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0341 · Cited by 139
Navabi, H., Jasani, B., Reece, A., Clayton, A., Tabi, Z., Donninger, C., Mason, M. D., & Adams, M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.024 · Cited by 135
Chow, L. Q. M., Morishima, C., Eaton, K. D., Baik, C. S., Goulart, B. H. L., Anderson, L. N., Manjarrez, K. L., Dietsch, G. N., Bryan, J. K., Hershberg, R. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1934 · Cited by 132
Salazar, A. Μ., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D. S., Mena, H., Martin, N. S., Schwab, K. A., Donovan, D., et al. (1996) · Neurosurgery · doi:10.1227/00006123-199606000-00006 · Cited by 129
Sharma, M. D., Rodríguez, P. C., Koehn, B. H., Baban, B., Cui, Y. R., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 127
Tsuji, T., Matsuzaki, J., Kelly, M. P., Ramakrishna, V., Vitale, L. A., He, L.-Z., Keler, T., Odunsi, K. O., Old, L. J., Ritter, G., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000808 · Cited by 120
CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells
Maurice, N. J., McElrath, M. J., Andersen-Nissen, E., Frahm, N., & Prlic, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12980-2 · Cited by 117
Gowen, B. B., Wong, M., Jung, K., Sanders, A. B., Mitchell, W. M., Alexopoulou, L., Flavell, R. A., & Sidwell, R. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5200 · Cited by 116
Cauwels, A., Lint, S. V., Paul, F., Garcin, G., Koker, S. D., Parys, A. V., Wueest, T., Gerlo, S., der Heyden, J. V., Bordat, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1980 · Cited by 104
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
Salazar, L. G., Lu, H., Reichow, J. L., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6007 · Cited by 101
Harrison, L. I., Astry, C. L., Kumar, S., & Yunis, C. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303766 · Cited by 80
Sittig, S. P., Bakdash, G., Weiden, J., Sköld, A. E., Tel, J., Figdor, C. G., de Vries, I. J. M., & Schreibelt, G. (2016) · Mediators of Inflammation · doi:10.1155/2016/3605643 · Cited by 77
Wang, D., Jiang, W. W., Zhu, F., Mao, X., & Agrawal, S. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4456 · Cited by 73
Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells
Aarntzen, E. H. J. G., Srinivas, M., Bonetto, F. J., Cruz, L. J., Verdijk, P., Schreibelt, G., van de Rakt, M. W. M. M., Lesterhuis, W. J., van Riel, M., Punt, C. J. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1879 · Cited by 62
Kodumudi, K. N., Ramamoorthi, G., Snyder, C., Basu, A. B., Jia, Y., Awshah, S., Beyer, A., Wiener, D. A., Lam, L., Zhang, H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01939 · Cited by 55
Soliman, H. H., Khambati, F. A., Han, H. S., Ismail-Khan, R. R., Bui, M. M., Sullivan, D. M., & Antonia, S. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24118 · Cited by 54
In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang, C. L.-L., & Kandalaft, L. E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.012 · Cited by 44
Tomasicchio, M., Semple, L., Esmail, A., Meldau, R., Randall, P. J., Pooran, A., Davids, M., Cairncross, L. L., Anderson, D. W., Downs, J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2238-5 · Cited by 42
Different maturation cocktails provide dendritic cells with different chemoattractive properties
Massa, C., Thomas, C., Wang, E., Marincola, F. M., & Seliger, B. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0528-7 · Cited by 38
Gilfillan, C. B., Kuhn, S. P., Baey, C., Hyde, E. J., Yang, J., Ruedl, C., & Ronchese, F. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701593 · Cited by 28
Inhibition of the IRE-1α/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice
Schutt, S. D., Wu, Y., Tang, C.-H. A., Bastian, D. A., Nguyen, H. D., Sofi, M. H., Zhang, M., Liu, C., Helke, K. L., Wilson, C. L., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017009068 · Cited by 27
Betts, B. C., Locke, F. L., Sagatys, E. M., Pidala, J., Walton, K., Menges, M. A., Reff, J., Saha, A., Djeu, J. Y., Kiluk, J. V., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02887 · Cited by 26
Cited by
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
RNA modifications: importance in immune cell biology and related diseases
Cui, L., Ma, R., Cai, J., Guo, C., Chen, Z., Yao, L., Wang, Y., Fan, R., Wang, X., & Shi, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01175-9 · Cited by 405
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P.-Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1110765 · Cited by 339
Metadata
- Authors
- Gardner, A., de Mingo Pulido, Á., & Ruffell, B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-05-21
- Volume
- 11
- Pages
- 924-924
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3028510355
- Cited by
- 485
- References
- 150
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.